Insider Selling: Mesa Laboratories (NASDAQ:MLAB) SVP Sells 2,516 Shares

Mesa Laboratories, Inc. (NASDAQ:MLAB) SVP Brian David Archbold sold 2,516 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total value of $225,182.00. Following the completion of the sale, the senior vice president directly owned 6,377 shares of the company’s stock, valued at $570,741.50. The trade was a 28.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Brian David Archbold also recently made the following trade(s):

• On Tuesday, June 16th, Brian David Archbold sold 1,151 shares of Mesa Laboratories stock. The shares were sold at an average price of $101.27, for a total value of $116,561.77.

Mesa Laboratories Trading Up 1.1%

NASDAQ:MLAB traded up $1.05 during midday trading on Tuesday, hitting $94.28. 64,805 shares of the company traded hands, compared to its average volume of 138,158. The firm’s fifty day moving average is $101.95 and its 200-day moving average is $90.98. Mesa Laboratories, Inc. has a 12-month low of $55.45 and a 12-month high of $113.99. The firm has a market capitalization of $520.90 million, a P/E ratio of 78.57 and a beta of 0.94. The company has a current ratio of 1.72, a quick ratio of 1.29 and a debt-to-equity ratio of 0.78.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.78 by ($0.25). The company had revenue of $63.72 million during the quarter, compared to the consensus estimate of $65.21 million. Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.During the same quarter in the prior year, the business earned ($1.31) earnings per share.

Mesa Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 15th. Stockholders of record on Friday, May 29th were paid a $0.16 dividend. The ex-dividend date of this dividend was Friday, May 29th. This represents a $0.64 annualized dividend and a dividend yield of 0.7%. Mesa Laboratories’s dividend payout ratio is currently 53.33%.

Institutional Investors Weigh In On Mesa Laboratories

Several hedge funds and other institutional investors have recently modified their holdings of MLAB. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Mesa Laboratories by 5,366.7% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 322 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Mesa Laboratories in the 4th quarter valued at $27,000. Kestra Advisory Services LLC bought a new position in Mesa Laboratories in the 4th quarter valued at $55,000. BNP Paribas Financial Markets grew its position in Mesa Laboratories by 115.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 786 shares of the medical instruments supplier’s stock valued at $74,000 after acquiring an additional 421 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Mesa Laboratories by 432.9% in the second quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock worth $79,000 after purchasing an additional 684 shares during the period. 90.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, June 3rd. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus price target of $94.00.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.